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Abstract
In two recent CKJ reviews, experts (Basile and Lomonte and Locatelli et al.) have reviewed haemodialysate composition. A long-
neglected issue, observational studies have associated the composition of haemodialysate to adverse outcomes. However, the
scarcity of clinical trial-derived information results in limited guideline recommendations on the issue. Indeed, guidelines have
more frequently indicated what not to do rather than what to do. In this setting, expert opinion becomes invaluable. In
designing haemodialysate composition, a balance should be struck between the need to correct within a time frame of around 4
hours the electrolyte and water imbalances that take 48 to 72 h to build, with the need for gradual correction of these
imbalances. The issue is complicated further by the impact of individual variability in dietary habits, medications and
comorbidities. In this regard, a personalizedmedicine approach to individualization of haemodialysate composition offers the
best chance of improving patient outcomes. But how can haemodialysate individualization be achieved, and what clinical trial
design will best test the impact of such approaches on patient outcomes?
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Chronic kidney disease (CKD) is one of the top fastest growing
causes of death worldwide [1]. This is an awkward position
when end-stage renal failure is treatable by dialysis or trans-
plantation [2]. Lack of access of millions of persons to renal
replacement therapy is amajor contributor tomortality [3]. How-
ever, current dialysis techniquesmay be optimized in order to in-
crease patient survival and quality of life. In this regard, there is a
current debate on the timing of dialysis initiation, especially for
the elderly, which is reﬂected in widely differing practices
throughout Europe andwhichmayalso be impacted by optimiza-
tion of dialysis [4]. Indeed, renal replacement therapy complica-
tions were the primary cause of death in 2.1% of patients in the
2000s [5]. Furthermore, observational studies have associated
haemodialysate composition with mortality [2]. Thus, high hae-
modialysate bicarbonate and low haemodialysate potassium
have been associated with increased mortality [6, 7]. However,
there is very little information derived from clinical trials. This
may be one of the reasons for the striking absence of recommen-
dations on haemodialysate composition frommost recent guide-
lines on haemodialysis prescription and adequacy. In this regard,
there are no recent suggestions for haemodialysate potassium
concentration and the only recent guideline to mention haemo-
dialysate bicarbonate advocates increasing the bicarbonate
concentration to 40 mmol/L as a means of achieving the target
pre-dialysis serum bicarbonate concentration (Table 1) [8, 9, 10].
Other guidelines explicitly indicate what concentrations to avoid,
but do not recommend the actual concentrations to use [11–13].
At this relatively early stage of understanding the optimal haemo-
dialysate composition, expert opinion becomes invaluable, not
only to provide guidance for current practice, but also and above
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all, to help understand the issues involved, identify the key unmet
needs and unanswered questions, and help plan the best way for-
ward research-wise. Two recent CKJ reviews led by experts in the
ﬁeld, Basile and Lomonte [8] and Locatelli et al. [9] have reviewed
haemodialysate composition.
Basile and Lomonte and Locatelli et al. review the haemodia-
lysate concentrations of sodium, potassium, calcium, magne-
sium and bicarbonate, and the main conclusions are
summarized in Tables 1 and 2 [8, 9]. Both authors emphasize
that in designing haemodialysate composition, a balance should
be struck between the need to correct within a time frame of
around 4 h the electrolyte and water imbalances that took 48–
72 h to build, with the need for gradual correction of these imbal-
ances. Overall, correction of imbalances impacts more on the
long-term outcomes of the patients. However, the speed of cor-
rection or overcorrection may have an acute impact in the form
of arrhythmia, as is the case for hypokalaemia, and calcium hae-
modialysate prescriptions that decrease serum calcium, espe-
cially if both are associated with metabolic alkalosis resulting
from high haemodialysate bicarbonate that further reduces io-
nized calcium and potassium. The issue is complicated further
by the impact of individual variability in dietary habits, medica-
tions and comorbidities. In this regard, a personalized medicine
approach to individualization of haemodialysate composition of-
fers the best chance of improving patient outcomes. However,
haemodialysate individualization may not be as easy as it
sounds, and no trial has assessed the different possible strategies
in terms of hard outcomes.
A common theme to decrease the speed of correction of the
imbalances is to keep those imbalances to aminimum [8, 9]. Diet-
ary counselling and oral medication may play a key role here.
Thus, a low salt diet will decrease the need for ultraﬁltration
and for a negative sodium balance. This is an important but
often forgotten concept and some health care personnel insist
more on the amount of ﬂuid ingested, although salt ingestion is
the key driver of thirst. Similarly, a low potassium dietary intake
or the use of potassium binders or even diuretics, as well as the
prescription of oral bicarbonatewill mitigate the need for low po-
tassium or high bicarbonate haemodialysate. In this regard, hae-
modialysate prescription should be viewed as an additional tool,
not just the only tool, in a holistic approach to patient care and
correction of hydroelectrolyte imbalances. In any case,we should
remember that haemodialysate individualization requires actual
assessment of the individual patient needs. Thus, haemodialy-
sate bicarbonate cannot be individualized if serum bicarbonate
is not monitored before and after haemodialysis.
For sodium and potassium, the main issue is how to make a
negative balance during haemodialysis that keeps the overall bal-
ance for the interdialytic-plus-haemodialysis-session period
neutral in such a way that hypotension and arrhythmia are
avoided by providing a smooth, adequate rate of removal. Vol-
ume status and serum potassium are used as targets. Calcium
presents additional issues, given the highly variable calcium ab-
sorption from dietary sources or medications, the highly variable
bone response and the different factors impacting on serum cal-
cium, from serum albumin levels to acid-base balance and the
use of medications such as cinacalcet. In Basile and Lomonte’s
words, ‘Which is the ideal haemodialysate calcium concentra-
tion is probably an unanswerable question.’ [8]. This is a sad real-
ization for nephrologists who ﬁll millions of prescriptions for
haemodialysate calcium concentrations every year. Thus, a key
priority here is to develop the techniques that will allow the rou-
tine estimation of calcium balance in the clinic in order to pre-
vent long-term calcium loading or depletion. Probably as aT
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consequence of the current uncertainties regarding haemodialy-
sate calcium, Basile and Lomonte and Locatelli et al. reach what
might look like different summary conclusions on the optimal
concentration [8, 9] (Table 1). However, Locatelli et al. do point
out that individualization may be considered in certain patients
and suggest that in patients on cinacalcet the low serum calcium
may lead to a high positive calcium balancewhen higher haemo-
dialysate calcium is used. This is illustrated by a recent case
report of lethal calciphylaxis despite long-term control of hyper-
parathyroidismwith paricalcitol and cinacalcet, and low-normal
serum calcium [15]. The long-term combination of oral 1.5–2.0 g
elemental calcium daily with 1.5 mmol/L haemodialysate cal-
cium may have contributed to progressive calcium overload. In
our own experience, individualization of dialysate calcium con-
centration according to baseline pre-dialysis serum calcium
may prevent major excursions in post-dialysis serum calcium
and intact parathyroid hormone levels [16]. Thus, the mildest
dialysis-induced changes in serum calcium and PTH were ob-
served in patients with pre-dialysis serum calcium <8.75 mg/dL
dialysed with 1.25 mmol/L haemodialysate calcium and in pa-
tients with pre-dialysis serum calcium >9.15 mg/dL dialysed
with 1.50 mmol/L haemodialysate calcium.
The case of magnesium is striking. It is probably the less
understood of haemodialysate components and serum magne-
sium is frequently notmonitored inhaemodialysis patients. Com-
mercially available haemodialysate magnesium concentration is
usually 0.25–0.75 mmol/L (a 3-fold difference!) and there are
even solutions with 0 and 1 mmol/L. A key piece of missing infor-
mation that can only be answered through clinical trials, is which
is the optimal serummagnesiumconcentration. In this regard, ob-
servational studies recently reported a survival beneﬁt for haemo-
dialysis patients with mild hypermagnesemia, as opposed to
those with higher and lower magnesium concentrations, includ-
ing those with magnesium within the normal range [17].
Both Basile and Lomonte and Locatelli et al. concur with the
need to individualize haemodialysate bicarbonate concentration
[8, 9]. This is a key concept, since many dialysis units do not rou-
tinely assess serum bicarbonate pre-dialysis and even less have
an idea of the post-dialysis serum bicarbonate in their patients.
However, clinical trials are needed that provide insights into
the optimal way to individualize haemodialysate bicarbonate
concentration and what serum bicarbonate targets and haemo-
dialysate bicarbonate concentrations improve outcomes.
Bicarbonate-based haemodialysate contains small amounts of
acetate. An issue not discussed in the CKJ reviews is the possibil-
ity to replace this acetate with citrate (acetate-free haemodialy-
sate). Limited clinical experience suggests that the short-term
(months) use of such citrate-enhanced haemodialysate is safe
and decreases haemodialysis-induced hypotension andmalaise,
the intra-dialytic shift in pH and base excess and post-dialysis
plasma ionized calcium levels, increasing post-dialysis PTH le-
vels, as compared with conventional haemodialysate, without
affecting pre-dialysis values, and also caused an intra-dialytic in-
crease in activated partial thromboplastin time [18–20].
Locatelli et al. further discuss haemodialysate composition in
special situations, including long nocturnal haemodialysis, daily
short haemodialysis, less frequent haemodialysis, on-line hae-
modiaﬁltration, as well as haemodialysate glucose concentration
and the possibility to enhance thehaemodialysatewith addition-
al phosphate or iron, such as ferric pyrophosphate citrate, in spe-
ciﬁc patient populations [9, 21, 22].
In conclusion, haemodialysate composition has been ne-
glected for too long in an environment dominated by a restrictive
concept of dialysis adequacy focused on the clearance of uraemic
toxins as categorized by the Kt/Vurea. However, there is accumu-
lating evidence that adequacy should be more broadly deﬁned,
encompassing not only the dose of urea clearance, but also
the dose of each individual component of the haemodialysate.
Observational data suggest that some currently used haemo-
dialysate concentrations of potassium and bicarbonate are asso-
ciated with increased mortality. Now, two updated and in-depth
reviews by experts provide guidance for routine prescription
of haemodialysate composition and identify key issues that
should be addressed preferentially through well-designed clinic-
al trials that embrace the complexity of end-stage kidney disease
patients and the interplay between different haemodialysate
components (Table 2) [8, 9]. Individualization is proposed for sev-
eral haemodialysate components. However, routine, technical or
knowledge limitations, or lack of monitoring of plasma para-
meters may preclude the widespread use of individualized
haemodialysate.
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Table 2. Unsolved issues related to haemodialysate composition [8, 9, 14]
Sodium
Beneﬁts and harm of ﬁxed (either low or high) haemodialysate sodium prescription
Impact on mortality of ﬁxed, individualized or real-time-modelled haemodialysate sodium
Potassium
Role of potassium proﬁling to prevent arrhythmia in the ﬁrst 2 h of haemodialysis
(Related: role of new oral potassium binders to allow a lower plasma-haemodialysate potassium gradient)
Calcium
How to assess and monitor calcium balance as a tool to guide haemodialysate calcium concentration
What haemodialysate calcium concentration maintains each individual patient in overall neutral calcium balance without promoting
CKD-mineral bone disorder?
What is the role of calcium proﬁling?
Magnesium
What is the optimal target serum magnesium concentration?
Bicarbonate
Randomized trial to assess the impact of different haemodialysate bicarbonate concentrations on mortality
Other haemodialysate components
What is the role of haemodialysate containing ferric pyrophosphate citrate in the management of iron deﬁciency?
Should acetate or citrate accompany bicarbonate in haemodialysate?
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Clin Kidney J (2015) 8: 580–589.)
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